Ascendiant Capital Markets Issues Positive Forecast for Atossa Genetics (NASDAQ:ATOS) Stock Price

Key Points

• Ascendiant Capital Markets has increased its price target for Atossa Genetics (NASDAQ:ATOS) from $7.50 to $7.75, maintaining a "buy" rating for the stock.
• The current average target price for Atossa Genetics is $6.25, with one analyst giving it a "strong buy" and two others rating it as a "buy".
• Despite a recent drop of 3.5% in share price, Atossa Genetics reported a quarterly EPS of (-$0.07), slightly missing analysts' expectations.

Atossa Genetics (NASDAQ:ATOS - Get Free Report) had its price target upped by research analysts at Ascendiant Capital Markets from $7.50 to $7.75 in a research report issued on Monday,Benzinga reports. The firm presently has a "buy" rating on the stock.

Separately, Craig Hallum raised Atossa Genetics to a "strong-buy" rating and set a $4.00 price target for the company in a report on Thursday, June 5th. One equities research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. According to MarketBeat.com, Atossa Genetics currently has a consensus rating of "Buy" and an average target price of $6.25.

Atossa Genetics Trading Down 3.5%

Shares of NASDAQ:ATOS opened at $0.85 on Monday. The company has a market cap of $109.63 million, a PE ratio of -3.69 and a beta of 1.10. Atossa Genetics has a twelve month low of $0.55 and a twelve month high of $1.66. The company's 50 day moving average is $0.81 and its 200 day moving average is $0.79.

Atossa Genetics (NASDAQ:ATOS - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.01). Equities research analysts predict that Atossa Genetics will post -0.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Atossa Genetics

Large investors have recently added to or reduced their stakes in the stock. Two Sigma Advisers LP raised its position in Atossa Genetics by 214.1% during the 4th quarter. Two Sigma Advisers LP now owns 42,400 shares of the company's stock worth $40,000 after purchasing an additional 28,900 shares during the last quarter. Millennium Management LLC purchased a new position in shares of Atossa Genetics in the 4th quarter worth approximately $28,000. Hudson Bay Capital Management LP bought a new stake in shares of Atossa Genetics in the 2nd quarter worth approximately $26,000. Bank of America Corp DE raised its holdings in shares of Atossa Genetics by 55.7% in the 2nd quarter. Bank of America Corp DE now owns 99,601 shares of the company's stock worth $83,000 after purchasing an additional 35,629 shares during the period. Finally, Catalyst Funds Management Pty Ltd bought a new stake in Atossa Genetics during the 2nd quarter valued at $49,000. Institutional investors and hedge funds own 12.74% of the company's stock.

Atossa Genetics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.